Merck, Moderna say phase 3 melanoma trial met two endpoints
Merck and Moderna say the phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met recurrence-free survival and distant metastasis-free survival endpoints in completely resected Stage IIB-IV melanoma.
Story updates
10:46:53 AM UTC
SquawkNews
MRK MRNA Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.